Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19300134 | DURABLE ANTI-FUNGAL AND ALGAE RESISTANT COATINGS | August 2025 | November 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18964814 | PHARMACEUTICAL COMPOSITIONS | December 2024 | January 2026 | Allow | 14 | 2 | 0 | Yes | No |
| 18780575 | SUBCUTANEOUS INJECTION METHOD FOR PAIN TREATMENT | July 2024 | October 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18779499 | PHARMACEUTICAL COMPOSITIONS | July 2024 | September 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18679670 | INTRANASAL ADMINISTRATION OF ESKETAMINE | May 2024 | April 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18636861 | METHOD FOR TREATING BURNS WITH BRAZILIAN GREEN PROPOLIS | April 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18411773 | PHARMACEUTICAL COMPOSITIONS | January 2024 | May 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18543053 | TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF | December 2023 | January 2026 | Abandon | 25 | 1 | 0 | No | No |
| 18511109 | GREEN NANOPARTICLE COMPOSITION FOR TREATMENT OF HISTOPLASMOSIS | November 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18511120 | METHOD FOR PREPARING SELF-ASSEMBLED NANOPARTICLE RELEASING SOLUBLE MICRONEEDLE STRUCTURE | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18386157 | 6'-(2-BROMOPHENYL)-2'-METHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUND | November 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18386081 | METHOD FOR AMELIORATING AUTISM SYMPTOMS BY PHARMACOLOGICAL ACTIVATION OF THE NEUROTENSIN RECEPTOR 1 (NTSR1) | November 2023 | September 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18383061 | METHOD FOR STABILIZING RETINOIC ACID PRECURSORS AND A SKIN BENEFIT COMPOSITION WITH STABILIZED RETINOIC ACID PRECURSORS | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18554250 | TREATMENT OF ESSENTIAL TREMOR | October 2023 | March 2026 | Abandon | 29 | 1 | 0 | No | No |
| 18238922 | COMPOSITIONS OF AND METHODS FOR DAIRY ANIMAL TEAT DIP | August 2023 | August 2025 | Allow | 23 | 2 | 0 | No | No |
| 18452455 | ALOE VERA COMPOSITIONS AS DRESSING MATERIAL AND RELATED METHODS OF PRODUCTION | August 2023 | August 2025 | Allow | 24 | 0 | 0 | Yes | No |
| 18277150 | VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF URINARY TRACT INFECTIONS | August 2023 | August 2025 | Allow | 24 | 0 | 0 | Yes | No |
| 18273467 | MONOVALENT COPPER/PORPHYRIDIUM SP. POLYSACCHARIDE COMPLEXES, RELATED PRODUCTS AND METHODS OF PREPARATION THEREOF | July 2023 | January 2026 | Abandon | 30 | 0 | 1 | No | No |
| 18355475 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18347211 | Novel Topical Skin Closure Compositions and Systems | July 2023 | November 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 18215019 | ANTIMICROBIAL OR WOUND CARE MATERIALS, DEVICES AND USES | June 2023 | April 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18269291 | COMPOUND OF ELEMENT ACID, WHICH IS IN ALLOTROPIC FORM, WHICH ENTERS INTO CELLULAR INTERACTION IN SOME BONE DISEASES | June 2023 | July 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18335973 | Antimicrobial bone cement | June 2023 | December 2025 | Allow | 30 | 1 | 0 | No | No |
| 18204436 | Marine polysaccharide vector-based anthocyanin nanoparticles, and preparation method therefor and application thereof in targeted delivery | June 2023 | September 2025 | Allow | 28 | 1 | 1 | No | No |
| 18203640 | COMPOSITIONS AND THERAPEUTIC METHODS FOR TREATING CHRONIC SEQUALAE FOLLOWING VIRAL INFECTIONS | May 2023 | June 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18038738 | MOLECULAR BASIS OF FATTY LIVER INHIBITION BY SODIUM BORATES | May 2023 | October 2025 | Allow | 28 | 1 | 0 | No | No |
| 18200765 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18037271 | NANOZYME COMPOSITIONS AND METHODS OF TREATMENT | May 2023 | March 2026 | Allow | 34 | 0 | 1 | Yes | No |
| 18314432 | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING CALCIUM RELATED DEGENERATIVE DISEASES, OSTEOPOROSIS OR CANCERS COMPRISING SIGMA ANTI-BONDING MOLECULE CALCIUM GLUCONATE | May 2023 | December 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18309198 | ATOMIZER APPARATUS AND METHODS OF USE THEREOF | April 2023 | January 2026 | Allow | 33 | 2 | 0 | Yes | No |
| 18031058 | 1-ALKOXYETHYL-3-ISOBUTYL-BENZENE AND 1-CARBOXYETHYL-3-ISOBUTYL-BENZENE AS AROMA INGREDIENTS | April 2023 | October 2025 | Allow | 30 | 0 | 1 | Yes | No |
| 18125468 | COMPOSITIONS AND METHODS FOR REDUCING GREENHOUSE GAS | March 2023 | February 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18124772 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | March 2023 | December 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18026261 | COMPOSITION COMPRISING SALVIA MILTIORRHIZA EXTRACT AS ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF DEPRESSION IN MENOPAUSAL WOMEN | March 2023 | March 2026 | Abandon | 36 | 2 | 0 | Yes | No |
| 18024173 | FORSYTHIA SUSPENSA COMPONENT AND OPTIONAL PANAX GINSENG COMPONENT AND THE APPLICATION | March 2023 | January 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18040022 | APOTHECARIAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | January 2023 | November 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18160445 | Lyophilized compositions comprising arsenic | January 2023 | June 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18100700 | PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOF | January 2023 | May 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18154879 | Method for inhibiting infection of SARS-CoV-2 in a Subject | January 2023 | March 2026 | Allow | 38 | 3 | 0 | No | No |
| 18015545 | A PERSONAL CARE COMPOSITION COMPRISING ATRACTYLENOLIDE-I OR A SOURCE THEREOF | January 2023 | January 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18092899 | Stable Botanical Antimicrobial Compositions | January 2023 | November 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18069902 | P2ET REDUCES COVID SEVERITY BY INHIBITION OF VIRAL REPLICATION, REDUCTION OF PULMONAR FIBROSIS MARKERS AND MODULATION OF INMUNE RESPONSE | December 2022 | March 2026 | Abandon | 39 | 1 | 1 | No | No |
| 18002669 | Compositions and Uses Thereof | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18086286 | OPHTHALMIC SUSPENSION COMPOSITION | December 2022 | December 2025 | Allow | 36 | 3 | 0 | Yes | No |
| 18068762 | DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME | December 2022 | December 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 18062678 | ANTISEPTIC WOUND DRESSING | December 2022 | November 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17967244 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINE | October 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 17890039 | INTRANASAL ADMINISTRATION OF ESKETAMINE | August 2022 | February 2024 | Abandon | 18 | 2 | 0 | No | No |
| 17789648 | DOSAGE REGIME WITH ESKETAMINE FOR TREATING NEUROPSYCHIATRIC OR NEUROLOGICAL CONDITIONS | June 2022 | August 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17785202 | Eyelash Extension Adhesive | June 2022 | May 2025 | Allow | 35 | 0 | 0 | No | No |
| 17784157 | COMPOSITIONS AND METHODS FOR MANAGING INFECTIONS OF A URINARY TRACT | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | Yes | No |
| 17829736 | PHARMACEUTICAL COMPOSITIONS | June 2022 | August 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17752418 | CONTROLLED RELEASE SYSTEM FOR PULMONARY DELIVERY OF SURFACTANT PROTEIN D | May 2022 | July 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17750760 | Antimicrobial Polymer Composite | May 2022 | September 2025 | Abandon | 40 | 5 | 1 | No | No |
| 17625385 | MEDICAL INSTRUMENT | April 2022 | March 2026 | Allow | 50 | 1 | 0 | Yes | No |
| 17660515 | Articles with Active Agent Concentrated at the Substrate Contacting Surface and Related Methods | April 2022 | August 2024 | Allow | 28 | 2 | 1 | No | No |
| 17724997 | ORGANOHYDROGEL FIBERS FOR SIMULTANEOUS RELEASE CONTROL OF HYDROPHILIC AND HYDROPHOBIC SUBSTANCES | April 2022 | November 2025 | Abandon | 42 | 2 | 1 | Yes | No |
| 17724105 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | April 2022 | April 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17715274 | MULTI-PHASE DELIVERY COMPOSITIONS AND PRODUCTS INCORPORATING SUCH COMPOSITIONS | April 2022 | January 2026 | Allow | 46 | 2 | 0 | Yes | Yes |
| 17713573 | METHOD FOR STABILIZING RETINOIC ACID PRECURSORS AND A SKIN BENEFIT COMPOSITION WITH STABILIZED RETINOIC ACID PRECURSORS | April 2022 | August 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17711932 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | April 2022 | May 2024 | Allow | 25 | 3 | 0 | No | No |
| 17697298 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF ANTIVIRAL AGENTS | March 2022 | January 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17642550 | INTRANASAL ADMINISTRATION OF ESKETAMINE | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17653838 | TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF | March 2022 | January 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17676573 | Compositions for Nanoemulsion Delivery Systems | February 2022 | October 2025 | Allow | 44 | 5 | 0 | Yes | No |
| 17671207 | PHARMACEUTICAL COMPOSITIONS | February 2022 | May 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17671157 | PHARMACEUTICAL COMPOSITIONS | February 2022 | May 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17552768 | PHARMACEUTICAL COMPOSITIONS | December 2021 | August 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17614020 | MICROBIOCIDAL DERIVATIVES | November 2021 | August 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17528877 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | November 2021 | January 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17609971 | PHOTOPROTECTIVE SYSTEM CONSISTING OF 4 SUNSCREENS | November 2021 | January 2026 | Abandon | 51 | 2 | 0 | No | No |
| 17595060 | FORMULATION CONTAINING CORNUS WILSONIANA EXTRACT AND USE THEREOF | November 2021 | October 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17608032 | SPRAYABLE ANTIMICROBIAL COATINGS FOR WOUND TREATMENTS | November 2021 | September 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17604768 | Method for Producing Cosmetic Solid Powder | October 2021 | November 2025 | Allow | 48 | 0 | 1 | Yes | No |
| 17502105 | USE OF ANIONIC CLAY IN PREPARING LEAD-REMOVING MEDICINE | October 2021 | November 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17602073 | CONSUMER PRODUCT WITH CONTROLLED RELEASE, BIODEGRADABLE CORE-SHELL MICROCAPSULE COMPOSITIONS | October 2021 | November 2025 | Allow | 49 | 3 | 0 | No | No |
| 17481651 | Anti-Microbial Agent | September 2021 | September 2023 | Abandon | 24 | 1 | 1 | No | No |
| 17447840 | PREVENTION OF LOCAL TUMOR RECURRENCE FOLLOWING SURGERY USING SUSTAINEDAND/OR DELAYED RELEASE OF MEDICAMENTS CONTAINED IN MICRO-PARTICLES | September 2021 | April 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17475622 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | September 2021 | April 2023 | Allow | 19 | 1 | 0 | No | No |
| 17410531 | Composition for Enhancing Hair Fiber Properties | August 2021 | April 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17430862 | AQUEOUS DISPERSION OF A COSMETIC PIGMENT AND A METHOD FOR PREPARING THE SAME | August 2021 | November 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17397378 | AEROSOL DEVICE FOR HAIR SHAPING AND/OR HAIRSTYLE HOLD | August 2021 | November 2023 | Allow | 27 | 0 | 0 | Yes | No |
| 17420300 | MINIMIZATION OF SYSTEMIC INFLAMMATION | July 2021 | October 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17362083 | METHOD FOR TREATING NOCICEPTIVE PAIN AND BURNS WITH BRAZILIAN GREEN PROPOLIS ALCOHOL EXTRACT | June 2021 | April 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17327952 | Novel Antimicrobial Topical Skin Closure Compositions and Systems | May 2021 | September 2024 | Allow | 39 | 0 | 0 | Yes | No |
| 17295993 | ZINGIBER ZERUMBET EXTRACT FOR COMBATING DANDRUFF | May 2021 | December 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17295870 | COMBINATION OF GABOXADOL AND LITHIUM FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17295571 | COSMETIC MAKE-UP COMPOSITION WITH LONG-LASTING SKIN-PERFECTING EFFECT | May 2021 | March 2026 | Allow | 58 | 5 | 0 | No | No |
| 17293610 | ANTIPERSPIRANT OR DEODORANT COMPOSITION | May 2021 | July 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17057627 | COSMETIC COMPOSITION CONTAINING a-MANGOSTIN, METHOD FOR PREPARATION, AND USES THEREOF | May 2021 | August 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17316861 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | May 2021 | June 2023 | Abandon | 25 | 2 | 0 | No | Yes |
| 17291268 | CLAY MASK COMPOSITION AND METHOD FOR USING THE SAME | May 2021 | October 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17288792 | ZINC MOLYBDATE HAVING A TRICLINIC CRYSTAL STRUCTURE, AS AN ANTIMICROBIAL AGENT | April 2021 | August 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17237477 | BIOAVAILABLE MINERALS FOR THE MITIGATION OF PATHOGENS IN ANIMALS, A MANUFACTURING METHOD AND A TREATMENT METHOD | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17286322 | BUCCAL MICRO-EFFERVESCENT TABLET AND PREPARATION METHOD THEREOF | April 2021 | October 2024 | Allow | 42 | 2 | 0 | No | No |
| 17228309 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | April 2021 | March 2022 | Allow | 11 | 2 | 0 | Yes | No |
| 17284746 | Tamper-resistant drug dosage forms and methods of making and use thereof | April 2021 | July 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17284273 | OIL-IN-WATER EMULSION COSMETIC | April 2021 | February 2026 | Abandon | 58 | 4 | 0 | No | No |
| 17283241 | PHARMACEUTICAL COMPOSITION FOR POSTPARTUM RECOVERY AND TREATMENT OF PELVIC FLOOR DYSFUNCTION | April 2021 | December 2024 | Allow | 44 | 1 | 1 | No | No |
| 17282087 | NUTRITION-BASED SUPPORT FOR THE BODY'S OWN WOUND HEALING PROCESSES | April 2021 | April 2025 | Abandon | 48 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PALENIK, JEFFREY T.
With a 39.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PALENIK, JEFFREY T works in Art Unit 1615 and has examined 1,036 patent applications in our dataset. With an allowance rate of 56.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner PALENIK, JEFFREY T's allowance rate of 56.5% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PALENIK, JEFFREY T receive 2.16 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PALENIK, JEFFREY T is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +27.8% benefit to allowance rate for applications examined by PALENIK, JEFFREY T. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 31.7% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 71.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 72.9% of appeals filed. This is in the 61% percentile among all examiners. Of these withdrawals, 61.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 66.0% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.7% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.